Posts Tagged "prurigo nodularis"

There are 2 results found

Trevi Therapeutics Initiates Pivotal Clinical Trial of Nalbuphine® ER for the Treatment of Pruritus in Prurigo Nodularis

Pruritus Relief thru Itch-Scratch Modulation (“PRISM”) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks New Haven, CT, September 27, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER […]

Trevi Therapeutics Raises $50 Million Series C Financing Led by New Enterprise Associates

Company continuing the development of Nalbuphine® ER in chronic pruritus conditions New Haven, CT, July 20, 2017 – Trevi Therapeutics, Inc. (“Trevi” or the “Company”), announced today that the Company has completed a Series C financing of $50.5 million led […]